Aaron. Thanks,
segment. Now a building updates few progress Pharma strategic our resiliency #X priority three key for regarding on with our priorities, the of upon the recent and beginning
our for core. performance efficiency the and essential prioritization to is what enabler of in quarters and key service pharma matters to execution capabilities our products outstanding team's of has We're most, consistent and patients. been their a over leveraging the now, business operational The deliver of scale, breadth the number customers
component. Within program remains the a core, generics our critical
Sourcing, job managing Oak a performance service continues Our fulfilling Red is and delivery help to both cost which maximize supply to by do for its customers. mandate, anchored dual fantastic
I specialty customer-focused on team terrific while Tennessee, vaccines, extensively worked to specialty display distribution in when distribution of I recently for our maintaining saw prepare where pharmaceutical visited service COVID-XX products. mindset our La other Vergne, facility their for commercial our
quickly for meet pleased requirements support for care, us shipments customers which and the in enabling this successfully We're begin approval accessibility. immediately cold to rely for manner, following fall FDA complex to team navigated demand vaccines, immunization the convenience and our season. Our in chain time patients upon making
opportunities, and manufacturers, and our It cell recently sourcing excitement services business emerging hosted our our conference. to areas hear and partners customers We're team various the like industry annual supplier strategic committed biosimilars supporting hundreds energizing for partners to and and manufacturer of gene. around as such was
to investing important developed and to about confident and see reiterated our this continued a for both the We've drugs strategic are partner space. We focus strong specialty space. in on commercialized this business, manufacturers, downstream upstream, to momentum and being continue have our ability our be across in
XX% with billion sizable specialty revenue, very over today at Day CAGR are years. noted Investor in has grown X which a 'XX the in fiscal we We last at over $XX
with Navista are out investments will We offerings, over the that time. progress our scale in platform making building network
growth in value, on while Our differentiated practice driving model maintaining community is focused practice sharing oncology independence. and
being with clinicians approach through customer is and advisory engagement our Our refined board.
and developing on community long-term practice patient we and supporting focus clinical operational to Overall, solutions aligned the of physicians care. strategically allow that oncologists are independence needs drive
the its nuclear, across growth double-digit In and performance categories Theranostics. trajectory, our continues strong core with business
for Advancement, projects XX Center our for demand various with pipeline Theranostics increasing partners. experience with to our pharmaceutical at manufacturer than more stages our continue in We
on investment announced Day. we that at our We're Investor II progressing Phase
our highly and fiscal pre-commercial track already center to 'XX our to With utilized. manufacturing the and deliver nuclear with capability strong on foundation fiscal our investment, expansions commercial 'XX innovation according by center. pharmacy We're profits business central its are Our manufacturing in doubling of baseline. continued long-term the progressing our underway center and well plan of is to target relative
medical to and medical meaningfully two. turning Now delivered we profitability, has The more back-to-back to quarters of come. expect now improved business priority number and
address been As part of chain to the improvement distribution and our the #X we've products taking medical supply priority in core mitigating the challenges business, being plan, with inflation. action
by We constraints inflation 'XX, exit remain we on and global to impact the now the we're chain address to time supply pleased note we to target. are over of track XX% and fiscal
freight side, On while our overall we've international anticipated. in costs reflected as the results elevated, cost still seen lower
We to progress initiatives. inflation, additional mitigation seeing contracting our our offset as making continue to commercial execute our are our sourcing with initiatives actions, benefits such efforts from are and elevated
through Additionally, yielded grow X-point brand plan we've has action volume, which improvements. to Cardinal been Health taking our
two core important made launches specialty We products product have medical during making our distribution clinically critical differentiated are portfolio offering. investments for utilizing commercialization balanced line also products, our we're to highlighted extensions notable fill and which We've development portfolio a in new in our and gaps product within culminated quarter. the to approach
Feeding feeding anticipated enteral launched throughout home. We enteral U.S., help journey, hospital needs to Pump Kangaroo to more OMNI options patients their feeding meet to from with the designed our nutritional Enteral provide in their
length the to We oral our next-generation the to faster of medical infants independent develop stay. also the premature of a coordination device make to and transition help announced NICU trainer launch X.X, their skills with system feeding reduce help end designed and newborn
environment what see products we're the to for continuing of progress our to portfolio which us I'm able improving as actions Cardinal more leading key better as offense we to metrics for that brand making benefiting utilization from and be moving confidence grow Health and our our the growth turn an experience excited in our portfolio. playing to our indicators, can results the participate categories, such gives we'll forward. about patients overall medical do customer now We're health
that XX-point a beyond increase for seen noted back For reduction pre-pandemic we consistent seen multiyear low orders, further X And and example, loyalty we've are a in which distribution our customer product in the last now in we've at index with continued years improvement the Day. at our levels. score U.S. Investor
we're see Outside of In at-Home the shifts distribution, increasingly accelerate and strong home. we businesses. to to as product demand our Solutions, growth continuing care continue to
on Our team's operational in this bottom increased is in producing resulting line. efficiency business, contributions better focus operating to leverage the
wrap continuing the contributed execute initiatives to To management and to quarter. the up segment, Medical, savings SG&A across which the in simplification our we're the strong cost
priority shareholder capital. Finally, maximizing shareholder operational our cash #X, responsible and allocation We're maximizing creation. performance, through value value robust of creation improved flow
Aaron value flow our excess of enabled fiscal share creation generation As our confidence and capital of willingness to detailed, 'XX to repurchases, return through deployment. cash continued execution our our in shareholders our capital baseline evidence
M&A and in our continue additional With repurchases. flexibility, financial disciplined opportunistically evaluate share specialty potential we'll to
a both clear evaluate partners upstream specialty strategy, for growth long-term our and that range potential predicated elements downstream not on inorganic agilely to candidates continue the of or but are targets for investment. acquisition our We
with are review portfolio ongoing We business making on segment. progress the focused our and Medical
simplicity, While is our across us. the in still year opportunity team work has focus operations front and over there the significant realigning of past progress made our for and company,
with work in and evaluate business updates quarters. collaboratively committee to We to further initiatives additional provide coming creation continue review our to the value expect
health excited their critical To our most like partner. for year's close, highly momentum. upon and would as our great and role driven thank a team, I and last talented trusted quarter This to to care's first fulfilling we engaged are all had them efforts was by build
that, With your will questions. we take
